Forward Pharma Announces the Decision of the Technical Board of Appeal of the European Patent Office in the EP2801355 Appeal Hearing
COPENHAGEN, Denmark, Sept. 06, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (we, Forward or the Company), today announced that the Technical Board of Appeal (the TBA) of the European Patent Office (the EPO) has dismissed Forwards appeal of the previous decision of the EPO Opposition Division to revoke the EP2801355 patent (the 355 patent) following the oral hearing.
- COPENHAGEN, Denmark, Sept. 06, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (we, Forward or the Company), today announced that the Technical Board of Appeal (the TBA) of the European Patent Office (the EPO) has dismissed Forwards appeal of the previous decision of the EPO Opposition Division to revoke the EP2801355 patent (the 355 patent) following the oral hearing.
- The TBA made its decision after considering Forwards appeal against the decision of the Opposition Division and third-party submissions from several opponents.
- The TBA will issue detailed reasons for the decision in written form in due course, and following receipt and review of these, Forward will announce future plans for the Company.
- The denial of a petition for review would end the Opposition Proceeding in favor of the opponents.